Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sky Century InvestmentSKYI EV-to-EBIT is -12.91 as of Sep. 21, 2026. The stock has 5 warning signs investors should review. Among 682 Drug Manufacturers companies, Sky Century Investment ranks worse than 146627.42% on this metric.
Sky Century Investment (OTCPK:SKYI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sky Century Investment's Enterprise Value for the quarter that ended in May. 2026 was $2.91 Mil.
Sky Century Investment's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sky Century Investment's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sky Century Investment EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sky Century Investment's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sky Century Investment's EV-to-EBIT falls into.
Sky Century Investment's current Enterprise Value is $0.81 Mil.
Sky Century Investment's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sky Century Investment (SKYI) has a EV-to-EBIT of -12.91 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sky Century Investment and its competitors. According to the industry distribution chart, Sky Century Investment ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Sky Century Investment's EV-to-EBIT too high?
Sky Century Investment's current EV-to-EBIT is -12.91. Based on the distribution chart, Sky Century Investment ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Sky Century Investment's EV-to-EBIT compare to CBDY and NPHC?
According to the Drug Manufacturers industry distribution chart, Sky Century Investment ranks #999999 out of 682 companies for EV-to-EBIT. This places Sky Century Investment in the lower half of its industry. The industry median EV-to-EBIT is 16.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sky Century Investment and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sky Century Investment's current EV-to-EBIT is -12.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sky Century Investment stock overvalued right now?
Sky Century Investment (SKYI) has a current EV-to-EBIT of -12.91. The current EV-to-EBIT is -12.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sky Century Investment (SKYI), the current EV-to-EBIT is -12.91 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sky Century Investment Inc operates four primary business lines, with profits generated from IT Services, including Technical Support and Server Leasing, and from the sale of RSS feeds and Podcasts. The IT Services segment provides ongoing technical support, maintenance, system upgrades, and high-performance server leasing, supporting growing demand for cloud solutions, data management, and network infrastructure. The Company also owns the Cannabis News application, a mobile platform that aggregates cannabis-related news from diverse sources and delivers real-time updates, though it is not commercially viable and has not generated revenue to date. The Company operates in competitive markets across IT services, marketing services, RSS feed services, and the cannabis industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SKYI has been successfully added to your 
